SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT01627132

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

The purpose of this study is to assess whether dasatinib can be discontinued without occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in complete molecular remission (CMR) while on dasatinib.

NCT01627132 Chronic Myeloid Leukemia
MeSH:Leukemia Leukemia, Myeloid Leukemia, Myelogenous, Chronic, BCR-ABL Positive
HPO:Chronic myelogenous leukemia Leukemia Myeloid leukemia

1 Interventions

Name: Dasatinib

Description: 100mg QD
Type: Drug
Group Labels: 1


Primary Outcomes

Measure: The overall probability of maintenance of complete molecular remission at 12 months after stopping dasatinib.

Time: at 12 months

Secondary Outcomes

Measure: Rate of complete molecular remission that will be sustained after dasatinib rechallenge.

Time: at 12 months

Purpose: Treatment

Allocation: N/A

Single Group Assignment

There are 3 SNPs


1 F317L

- Patients with mutation of T315I, F317L, V299L. --- T315I --- --- F317L ---

2 T315I

- Patients with mutation of T315I, F317L, V299L. --- T315I ---

3 V299L

- Patients with mutation of T315I, F317L, V299L. --- T315I --- --- F317L --- --- V299L ---

HPO Nodes